UBS Group
IRLA

UBS Group’s IRulya Therapeutics Inc. Common Stock IRLA Stock Holding History

UBS Group’s Portfolio IRLA Stock Details IRLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$86K Buy
4,730
+4,727
+157,567% +$109K ﹤0.01% 7268
2026
Q1 		$56 Sell
3
-172
-98% -$34.5K ﹤0.01% 10192
2025
Q4 		$118K Buy
175
+168
+2,400% +$84.5K ﹤0.01% 6828
2025
Q3 		$2.4K Sell
7
-7
-50% -$2.33K ﹤0.01% 9176
2025
Q2 		$4.7K Buy
14
+10
+250% +$2.29K ﹤0.01% 9247
2025
Q1 		$939 Sell
4
-2
-33% -$611 ﹤0.01% 9612
2024
Q4 		$2.08K Buy
6
+4
+200% +$1.2K ﹤0.01% 9115
2024
Q3 		$373 Hold
2
– – ﹤0.01% 8972
2024
Q2 		$360 Sell
2
-1
-33% -$181 ﹤0.01% 8954
2024
Q1 		$536 Hold
3
– – ﹤0.01% 8496
2023
Q4 		$530 Sell
3
-30
-91% -$6.01K ﹤0.01% 8608
2023
Q3 		$7.47K Buy
33
+28
+560% +$7.32K ﹤0.01% 7230
2023
Q2 		$1.37K Buy
5
+3
+150% +$934 ﹤0.01% 7936
2023
Q1 		$507 Sell
2
-227
-99% -$44.4K ﹤0.01% 9001
2022
Q4 		$29.4K Buy
229
+62
+37% +$10.4K ﹤0.01% 7259
2022
Q3 		$44K Buy
167
+41
+33% +$15.6K ﹤0.01% 6475
2022
Q2 		$56K Sell
126
-2
-2% -$1.41K ﹤0.01% 5832
2022
Q1 		$158K Buy
128
+50
+64% +$68K ﹤0.01% 5548
2021
Q4 		$197K Sell
78
-7
-8% -$42.7K ﹤0.01% 5709
2021
Q3 		$1.56M Buy
85
+34
+67% +$541K ﹤0.01% 3805
2021
Q2 		$537K Sell
51
-128
-72% -$1.07M ﹤0.01% 4675
2021
Q1 		$1.29M Buy
179
+126
+238% +$907K ﹤0.01% 4000
2020
Q4 		$293K Sell
53
-49
-48% -$434K ﹤0.01% 4984
2020
Q3 		$1.02M Sell
102
-13
-11% -$118K ﹤0.01% 3623
2020
Q2 		$1.06M Sell
115
-15
-12% -$137K ﹤0.01% 3455
2020
Q1 		$1.19M Sell
130
-5
-4% -$49.4K ﹤0.01% 3208
2019
Q4 		$1.51M Buy
135
+51
+61% +$308K ﹤0.01% 3831
2019
Q3 		$418K Buy
84
+50
+147% +$308K ﹤0.01% 4709
2019
Q2 		$290K Buy
+34
New +$203K ﹤0.01% 4675

Other funds holding IRLA

Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
SC
Shay Capital New York $1.56B AUM 46.17% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

UBS Group's IRLA Position: Q2 2026 in Review

UBS Group increased its IRulya Therapeutics Inc. Common Stock (IRLA) stake by 157,567% in Q2 2026, buying an estimated $109K and bringing the position to 4,730 shares worth $86K. The position accounts for ﹤0.01% of the portfolio, ranked #7268.

UBS Group first reported a position in IRLA in Q2 2019 and has held it in 29 quarters since. The position peaked at $1.56M in Q3 2021. 26 funds tracked by Wall St. Rank hold IRLA as of Q2 2026.

  • UBS Group held 4,730 shares of IRulya Therapeutics Inc. Common Stock worth $86K as of Q2 2026.
  • UBS Group bought 4,727 IRulya Therapeutics Inc. Common Stock shares in Q2 2026, an estimated $109K.
  • IRulya Therapeutics Inc. Common Stock made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #7268 holding.
  • UBS Group first reported a position in IRulya Therapeutics Inc. Common Stock in Q2 2019 and has held it in 29 quarters since.
  • UBS Group's IRulya Therapeutics Inc. Common Stock position peaked at $1.56M in Q3 2021.
  • 26 funds tracked by Wall St. Rank held IRulya Therapeutics Inc. Common Stock as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.